Cantourage Group SE Acknowledges Clarity on GKV-FinStG Implementation

Cantourage Group SE has expressed approval of the recent clarification from the National Association of Statutory Health Insurance Physicians and the National Association of Statutory Health Insurance Funds in Germany concerning medical cannabis prescriptions. This clarification is crucial as it ensures that patients already using cannabis extracts or formulations with dronabinol or nabilone can continue their treatment without needing to switch to another medicinal product. This development provides much-needed legal clarity for both patients and healthcare providers.

Despite this regulatory update, Cantourage's business operations remain largely unaffected, given its limited engagement with the reimbursement process for compounded cannabis treatments. However, the company sees the legal certainty as a positive step toward enhancing patient access and improving planning for all market players.